TIDMABC
RNS Number : 1098A
ABCAM Plc
02 October 2009
?
+---------------------------------------+---------------------------------------+
| For immediate release | 2 October 2009 |
+---------------------------------------+---------------------------------------+
("Abcam" or "the Company")
Director's Dealings
Cambridge, UK: Abcam plc (AIM: ABC), the rapidly growing bioscience company that
markets antibodies via its own online catalogue, announces the following
transactions undertaken by Directors of the Company:
On 30 September 2009, Jonathan Milner, an Executive Director of the Company,
exercised share options over 53,571 ordinary shares of 1 pence each in the
Company at an exercise price of 280p per share. Following this transaction, Dr
Milner's total beneficial interest in the Company is 6,138,851 ordinary shares
representing approximately 17.2 per cent. of the current issued share capital of
the Company.
Also on 30 September 2009, Jim Warwick, an Executive Director of the Company,
exercised share options over 20,000 ordinary shares of 1 pence each in the
Company at an exercise price of 280p per share. Following this transaction, Mr
Warwick's total beneficial interest in the Company is 853,520 ordinary shares
representing approximately 2.4 per cent. of the current issued share capital of
the Company.
For further information please contact:
+-----------------------------------------+------------------------------------+
| Abcam | + 44 (0) 1223 696000 |
+-----------------------------------------+------------------------------------+
| Jonathan Milner, Chief Executive | |
| Officer | |
+-----------------------------------------+------------------------------------+
| Jeffrey Iliffe, Chief Financial Officer | |
+-----------------------------------------+------------------------------------+
| | |
+-----------------------------------------+------------------------------------+
| Numis Securities | + 44 (0) 20 7260 1000 |
+-----------------------------------------+------------------------------------+
| Michael Meade / Nick Westlake - | |
| Nominated Adviser | |
+-----------------------------------------+------------------------------------+
| James Black - Corporate Broking | |
+-----------------------------------------+------------------------------------+
| | |
+-----------------------------------------+------------------------------------+
| Buchanan Communications | + 44 (0) 20 7466 5000 |
+-----------------------------------------+------------------------------------+
| Mark Court / Mary-Jane Johnson / Stasa | |
| Filiplic | |
+-----------------------------------------+------------------------------------+
Notes for editors:
About Abcam plc
Abcam is a producer and distributor of research-grade antibodies headquartered
in Cambridge, United Kingdom, with offices in Cambridge, Massachusetts, USA and
Tokyo, Japan. Abcam was admitted to AIM in November 2005 and trades under the
ticker symbol ABC. The Company produces and distributes its own and third-party
produced antibodies to academic and commercial users throughout the world.
Product ordering is available through the Company's website www.abcam.com, where
customers are also able to access up-to-date and detailed technical product data
sheets. All the antibodies are sold under the Abcam brand name and the Company's
vision is to build the world's largest online resource of high-quality and
commercially viable antibodies. Abcam now has an online catalogue of over 52,000
products, most of which are antibodies, from over 250 suppliers and employs 237
staff in its three operating companies.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSVFLFBKBBBFBK
|